Tetrahydrocurcumin-loaded vaginal nanomicrobicide for prophylaxis of HIV/AIDS: in silico study, formulation development, and in vitro evaluation

Mirani, Amit; Kundaikar, Harish; Velhal, Shilpa; Patel, Vainav; Bandivdekar, A. H.; Degani, Mariam S.; Patravale, Vandana

doi:10.1007/s13346-019-00633-2

Cited by 27 publications

(32 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efficient microbicide action was displayed by a combination of a HIV reverse transcriptase-inhibiting drug (efavirenz) and an integrase inhibitor (elvitegravir) encapsulated in a graft copolymer of methoxypolyethylene glycol-polylysine with a fatty hydrophobic core. The developed nano-formulation exhibited a significant reduction of cytotoxicity and in vivo bio-distribution upon topical intravaginal administration [73]. A similar effect was demonstrated by Mirani et al [74], wherein a nano-formulation comprising a lipidic nano-microbicide gel was loaded with tetrahydrocurcumin.…”

Section: Sexually Transmitted Infections and Hivsupporting

confidence: 68%

Nanotechnology in reproductive medicine: Opportunities for clinical translation

Shandilya

Pathak

Lohiya

et al. 2020

Clin Exp Reprod Med

View full text Add to dashboard Cite

In recent years, nanotechnology has revolutionized global healthcare and has been predicted to exert a remarkable effect on clinical medicine. In this context, the clinical use of nanomaterials for cancer diagnosis, fertility preservation, and the management of infertility and other pathologies linked to pubertal development, menopause, sexually transmitted infections, and HIV (human immunodeficiency virus) has substantial promise to fill the existing lacunae in reproductive healthcare. Of late, a number of clinical trials involving the use of nanoparticles for the early detection of reproductive tract infections and cancers, targeted drug delivery, and cellular therapeutics have been conducted. However, most of these trials of nanoengineering are still at a nascent stage, and better synergy between pharmaceutics, chemistry, and cutting-edge molecular sciences is needed for effective translation of these interventions from bench to bedside. To bridge the gap between translational outcome and product development, strategic partnerships with the insight and ability to anticipate challenges, as well as an in-depth understanding of the molecular pathways involved, are highly essential. Such amalgamations would overcome the regulatory gauntlet and technical hurdles, thereby facilitating the effective clinical translation of these nano-based tools and technologies. The present review comprehensively focuses on emerging applications of nanotechnology, which holds enormous promise for improved therapeutics and early diagnosis of various human reproductive tract diseases and conditions.

show abstract

Section: Sexually Transmitted Infections and Hivsupporting

confidence: 68%

Nanotechnology in reproductive medicine: Opportunities for clinical translation

Shandilya

Pathak

Lohiya

et al. 2020

Clin Exp Reprod Med

View full text Add to dashboard Cite

show abstract

“…Mirani et al [46] studied the efficacy of tetrahydrocurcumin, a colourless metabolite of curcumin, either alone or formulated as a microemulsion (designated TME), as a potential vaginal microbicide for topical application as a prophylactic approach to prevent HIV infection. In a reporter cell line, TME showed greater HIV-1 inhibition than the drug alone (IC 50 of 0.9357 µM and 3.639 µM, respectively).…”

Section: Human Immunodeficiency Virusmentioning

confidence: 99%

“…In a reporter cell line, TME showed greater HIV-1 inhibition than the drug alone (IC 50 of 0.9357 µM and 3.639 µM, respectively). In a p24 antigen assay, 1 µM of TME also showed a greater ability to lower p24 levels over a 10-day time course of infection compared to 5 µM of tetrahydrocurcumin [46]. To further validate the potential of TME as a vaginal microbicide, the effect of TME on Lactobacillus species was evaluated, as these bacteria form part of the natural microbiota and are important for maintaining the acidic environment of the FGT [47].…”

Section: Human Immunodeficiency Virusmentioning

confidence: 99%

“…To further validate the potential of TME as a vaginal microbicide, the effect of TME on Lactobacillus species was evaluated, as these bacteria form part of the natural microbiota and are important for maintaining the acidic environment of the FGT [47]. No change in viability was observed at any concentration for L. casie and L. acidophilus [46]. Finally, the authors showed that both TME and tetrahydrocurcumin were efficacious when formulated into suspension gels, which would be easy to apply, with no loss of anti-HIV-1 efficacy.…”

Section: Human Immunodeficiency Virusmentioning

confidence: 99%

See 1 more Smart Citation

Curcumin as an Antiviral Agent

Jennings

Parks

2020

Viruses

121

View full text Add to dashboard Cite

show abstract

“…An increased adhesion and retention time in the vaginal mucosa could also be obtained by adding a gelling polymer to an O/W microemulsion, as in study by Mirani et al (2019). This microemulsion gel was loaded with a curcumin derivative explored for the prophylaxis of HIV-1 infection.…”

Section: Aidsmentioning

confidence: 99%

Recent Advances in Nanosystems and Strategies for Vaginal Delivery of Antimicrobials

et al. 2021

View full text Add to dashboard Cite

Vaginal infections such as bacterial vaginosis (BV), chlamydia, gonorrhea, genital herpes, candidiasis, and trichomoniasis affect millions of women each year. They are caused by an overgrowth of microorganisms, generally sexually transmitted, which in turn can be favored by alterations in the vaginal flora. Conventional treatments of these infections consist in systemic or local antimicrobial therapies. However, in the attempt to reduce adverse effects and to contrast microbial resistance and infection recurrences, many efforts have been devoted to the development of vaginal systems for the local delivery of antimicrobials. Several topical dosage forms such as aerosols, lotions, suppositories, tablets, gels, and creams have been proposed, although they are sometimes ineffective due to their poor penetration and rapid removal from the vaginal canal. For these reasons, the development of innovative drug delivery systems, able to remain in situ and release active agents for a prolonged period, is becoming more and more important. Among all, nanosystems such as liposomes, nanoparticles (NPs), and micelles with tunable surface properties, but also thermogelling nanocomposites, could be exploited to improve local drug delivery, biodistribution, retention, and uptake in vulvovaginal tissues. The aim of this review is to provide a survey of the variety of nanoplatforms developed for the vaginal delivery of antimicrobial agents. A concise summary of the most common vaginal infections and of the conventional therapies is also provided.

show abstract

Tetrahydrocurcumin-loaded vaginal nanomicrobicide for prophylaxis of HIV/AIDS: in silico study, formulation development, and in vitro evaluation

Cited by 27 publications

References 37 publications

Nanotechnology in reproductive medicine: Opportunities for clinical translation

Nanotechnology in reproductive medicine: Opportunities for clinical translation

Curcumin as an Antiviral Agent

Recent Advances in Nanosystems and Strategies for Vaginal Delivery of Antimicrobials

Contact Info

Product

Resources

About